Pharmaceutical

Tevogen to go public in $1.2bn SPAC deal

The T-cell therapeutics company expects to be listed on the NYSE after deal completion in Q4 2023.

Jun 29, 2023 - 20:00
Tevogen to go public in $1.2bn SPAC deal
The T-cell therapeutics company expects to be listed on the NYSE after deal completion in Q4 2023.
Read the original article

Tags:

Previous Article

Lantidra wins FDA approval as first-ever type 1 diabetes cell therapy

Next Article

Q&A: How can the US maintain access to essential drugs?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira

STAT+: AbbVie CEO Gonzalez to step down after a decade ...

Feb 21, 2024

Asieris showcases Phase III win in treating precancerous cervical lesions

Asieris showcases Phase III win in treating precancerou...

Mar 20, 2024

Opinion: Pumping milk at JPM was a nightmare. It’s part of a bigger problem in the industry

Opinion: Pumping milk at JPM was a nightmare. It’s part...

Jan 12, 2024